Martin Elias Arrieta Mendoza

Martin Elias Arrieta Mendoza

Auto-generated profile, based on publicly available information

Martin Elias Arrieta Mendoza

Department of Internal Medicine, Faculty of Health, Universidad del Valle, Cali, Colombia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2018 in Revista Chilena de Anestesia
Verified
Journal Article
Open access
JTJesús H. H. Tovar
Jesús H. H. Tovar
MPMiguel A. Pinzón
Miguel A. Pinzón
DRDiego Rincón
Diego Rincón
CJCarlos Eduardo Jimenez-Canizales
Carlos Eduardo Jimenez-Canizales
MAMartín E. Arrieta-Mendoza
Martín E. Arrieta-Mendoza
ÁMÁlvaro Mondragón-Cardona
Álvaro Mondragón-Cardona

16 June 2026 in PLOS ONE
Verified
Journal Article
Open access
MAMartin E. Arrieta-Mendoza
Martin E. Arrieta-Mendoza
JBJuan R. Betancourt
Juan R. Betancourt
SASebastián Ayala-Zapata
Sebastián Ayala-Zapata
SBStephany Barbosa-Balaguera
Stephany Barbosa-Balaguera
CMChristian D. Messu-Llanos
Christian D. Messu-Llanos
OAOswaldo E. Aguilar-Molina
Oswaldo E. Aguilar-Molina
Sickle cell disease (SCD) is associated with substantial cardiovascular morbidity, but echocardiographic data from Latin American populations remain scarce. We aimed to characterise the structural, functional, and haemodynamic echocardiographic profile of adults with SCD attending a tertiary referral centre in Cali, Colombia. We conducted an observational, cross-sectional study based on systematic review of medical records and transthoracic echocardiography reports of consecutive adult patients (≥18 years) with confirmed SCD evaluated between January 2022 and December 2024. Patients with complex congenital heart disease, severe valvular disease of unrelated aetiology, pregnancy, or echocardiograms of insufficient quality were excluded. Of 669 patients screened, 57 met inclusion criteria. Reporting followed STROBE recommendations. The median age was 24 years (interquartile range [IQR] 21–32) and 59.6% were female; the SS genotype was the most frequent (76.4%) and 68.5% were on hydroxyurea. Median haemoglobin was 8.5 g/dL (IQR 7.1–10.0) and median NT-proBNP 491 pg/mL (IQR 98–1290). Most patients had preserved left ventricular dimensions and systolic function (median ejection fraction 63%, IQR 57–66.5; mean global longitudinal strain −18.9% ± 2.9). Right ventricular function was preserved (mean tricuspid annular plane systolic excursion 25.4 ± 4.6 mm). Left ventricular geometry was normal in 42.1%, with concentric remodelling in 10.5%, concentric hypertrophy in 21.1%, and eccentric hypertrophy in 26.3%. Diastolic function was normal in 71.4%. Valvular disease, when present, was predominantly mild. Tricuspid regurgitation velocity exceeded 2.5 m/s in 14 of 36 patients with measurable TRV (38.9%; 24.6% of the whole cohort) and exceeded 3.0 m/s in 6 patients (16.7% of those with measurable TRV), identifying a substantial subgroup at intermediate-to-high probability of pulmonary hypertension. In this Colombian cohort of relatively young adults with SCD, cardiac structure and biventricular function were largely preserved, but nearly one-third of patients had echocardiographic findings suggestive of pulmonary hypertension. These findings support the routine use of transthoracic echocardiography as an accessible tool for early cardiovascular risk stratification in adults with SCD in low- and middle-income settings.

20 April 2026 in medRxiv
Verified
Preprint
Open access
PDF file
MAMartín E. Arrieta-Mendoza
Martín E. Arrieta-Mendoza
JBJuan R. Betancourt
Juan R. Betancourt
SASebastián Ayala-Zapata
Sebastián Ayala-Zapata
SBStephany Barbosa-Balaguera
Stephany Barbosa-Balaguera
CMChristian D. Messu-Llanos
Christian D. Messu-Llanos
OAOswaldo E. Aguilar-Molina
Oswaldo E. Aguilar-Molina
Sickle cell disease (SCD) is associated with substantial cardiovascular morbidity, but echocardiographic data from Latin American populations remain scarce. We aimed to characterise the structural, functional, and haemodynamic echocardiographic profile of adults with SCD attending a tertiary referral centre in Cali, Colombia. We conducted an observational, cross-sectional study based on systematic review of medical records and transthoracic echocardiography reports of consecutive adult patients (≥18 years) with confirmed SCD evaluated between January 2022 and December 2024. Patients with complex congenital heart disease, severe valvular disease of unrelated aetiology, pregnancy, or echocardiograms of insufficient quality were excluded. Of 669 patients screened, 57 met inclusion criteria. Reporting followed STROBE recommendations. The median age was 24 years (interquartile range [IQR] 21–32) and 59.6% were female; the SS genotype was the most frequent (76.4%) and 71.4% were on hydroxyurea. Median haemoglobin was 10.2 g/dL (IQR 9.3–11.4) and median NT-proBNP 491 pg/mL (IQR 98–1290). Most patients had preserved left ventricular dimensions and systolic function (median ejection fraction 63%, IQR 57–66.5; mean global longitudinal strain −18.9% ± 2.9). Right ventricular function was preserved (mean tricuspid annular plane systolic excursion 25.4 ± 4.6 mm). Left ventricular geometry was normal in 42.1%, with concentric remodelling in 24.6%, concentric hypertrophy in 21.1%, and eccentric hypertrophy in 12.3%. Diastolic function was normal in 71.4%. Valvular disease, when present, was predominantly mild. Tricuspid regurgitation velocity exceeded 2.5 m/s in 29.8% of patients and exceeded 3.0 m/s in 10.5%, identifying a substantial subgroup at intermediate-to-high probability of pulmonary hypertension. In this Colombian cohort of relatively young adults with SCD, cardiac structure and biventricular function were largely preserved, but nearly one-third of patients had echocardiographic findings suggestive of pulmonary hypertension. These findings support the routine use of transthoracic echocardiography as an accessible tool for early cardiovascular risk stratification in adults with SCD in low- and middle-income settings.

14 July 2023 in Revista Colombiana de Endocrinología, Diabetes & Metabolismo
Verified
Journal Article
Open access
PDF file
ATAlejandro Pinzón Tovar
Alejandro Pinzón Tovar
LPLuis Carlos Álvarez Perdomo
Luis Carlos Álvarez Perdomo
LLLina María Leiva
Lina María Leiva
MMMartin Elias Arrieta Mendoza
Martin Elias Arrieta Mendoza
Context: Use of intermittent glucose monitoring in patients undergoing hemodialysis. Objective: To describe the behavior of glucose through intermittent monitoring in patients with chronic kidney disease undergoing hemodialysis. Methodology: An observational prospective study. Patients with chronic kidney disease of different causes undergoing hemodialysis were included. The glucometer readings results were analyzed before and during the renal hemodialysis session in 85 hospitalized patients; the glucometer readings values on the day of hemodialysis were studied in 47 outpatient patients. Results: For this study, 132 patients were included, with a median age of 61 years, 54.5% female, most of them from Neiva, Huila. 93.9% had a history of hypertension, 63.6% had anemia, and 53.8% had diabetes mellitus, with an average time of renal replacement therapy of 3.05 years. The average glucometer reading at the start of hemodialysis was 18.9 mg/dl higher, compared to the post-dialysis value among patients with diabetes and only 14.0 mg/dl in patients without diabetes. Regardless of the history of diabetes mellitus, the behavior of the glucometer readings was similar, with higher values at the start of therapy, followed by a subsequent decrease with few records of hypoglycemia. Conclusions: In patients with chronic kidney disease undergoing hemodialysis, intermittent capillary glucose monitoring shows behavior in blood glucose values that demonstrate an intradialysis decrease with subsequent elevation after finishing renal replacement therapy. Contexto: uso de monitoria intermitente de glucosa en pacientes que se encuentran en hemodiálisis. Objetivo: describir el comportamiento de la glucosa, mediante monitorización intermitente en pacientes con enfermedad renal crónica que se encuentran en hemodiálisis. Metodología: estudio observacional prospectivo. Se incluyeron pacientes con enfermedad renal crónica de diferentes causas que se encuentran en hemodiálisis. A su vez, se analizaron los resultados de las glucometrías antes y durante la sesión de hemodiálisis renal en 85 paciente hospitalizados, y posteriormente, se analizaron los valores de las glucometrías el día de hemodiálisis en 47 pacientes ambulatorios. Resultados: se incluyeron 132 pacientes con una mediana de edad de 61 años, 54.5% de sexo femenino, procedentes en gran parte de la ciudad de Neiva, Huila. El 93.9% tenían antecedentes de HTA; el 63.6% tenían anemia y el 53.8% diabetes mellitus, con un tiempo promedio de terapia de reemplazo renal de 3,05 años. El promedio de la glucometría al inicio de la hemodiálisis fue de 18,9 mg/dl mayor, respecto al valor postdiálisis entre los pacientes con diabetes, y solo de 14,0 mg/dl en los pacientes sin diabetes. Independientemente del antecedente de diabetes mellitus, el comportamiento de las glucometrías fue similar con valores más altos al inicio de la terapia observándose un descenso posterior con pocos registros de hipoglucemia. Conclusiones: en pacientes con enfermedad renal crónica que se encuentran en hemodiálisis el monitoreo intermitente de glucosa capilar, se evidencia un comportamiento en los valores de glucemia que muestran un descenso intradiálisis con elevación posterior al terminar la terapia de reemplazo renal.